消脂方通过激活AMPK与PPAR通路调控脂质代谢改善非酒精性脂肪肝
消脂方(XZF)是治疗非酒精性脂肪性肝病(NAFLD)的中药复方,已获国家发明专利。本研究采用UHPLC-Q-Orbitrap HRMS鉴定XZF成分,并在高脂饮食诱导的NAFLD小鼠模型中验证其疗效与机制。结果显示XZF可减轻肥胖、肝脏脂肪变性和氧化应激,改善糖脂代谢,其机制与激活AMPK和PPAR通路、调节脂质代谢基因表达有关。
要点
- XZF可减轻HFD诱导的小鼠肥胖、白色脂肪细胞增大和肝脏脂肪变性。
- XZF能改善糖脂代谢紊乱并预防氧化应激损伤。
- XZF通过激活AMPK和PPAR通路调节脂质代谢基因表达。
核心结论
- 消脂方通过激活AMPK和PPAR信号通路调节脂质代谢,从而减轻非酒精性脂肪性肝病的进展。
研究设计与样本
- 研究采用UHPLC-Q-Orbitrap HRMS鉴定消脂方成分,并建立高脂饮食诱导的NAFLD小鼠模型评估其疗效与机制。
主要发现
- 从消脂方中初步鉴定出120种化合物。
- 消脂方减轻HFD诱导的小鼠肥胖、白色脂肪细胞大小、脂质积累和肝脏脂肪变性。
- 消脂方使血糖水平正常化,改善糖脂代谢紊乱,并预防HFD诱导的氧化应激损伤。
- 蛋白质组学分析显示脂肪酸代谢和PPAR信号通路受消脂方显著影响,脂解和β氧化基因表达上调,脂肪酸合成基因表达下降。
- 消脂方增强肝脏p-AMPK、PPARα和CPT-1表达,抑制PPARγ表达。
临床怎么用
- 消脂方可作为治疗NAFLD的潜在中药复方,其作用机制涉及AMPK和PPAR通路的激活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xiaozhi formula (XZF) is a practical Chinese herbal formula for the treatment of non-alcoholic fatty liver disease (NAFLD), which possesses an authorized patent certificate issued by the State Intellectual Property Office of China (ZL202211392355.0). However, the underlying mechanism by which XZF treats NAFLD remains unclear. PURPOSE: This study aimed to explore the main component of XZF and its mechanism of action in NAFLD treatment. METHODS: UHPLC-Q-Orbitrap HRMS was used to identify the components of the XZF. A high-fat diet (HFD)-induced NAFLD mouse model was used to demonstrate the effectiveness of XZF. Body weight, liver weight, and white fat weight were recorded to evaluate the therapeutic efficacy of XZF. H&E and Oil Red O staining were applied to observe the extent of hepatic steatosis. Liver damage, lipid metabolism, and glucose metabolism were detected by relevant assay kits. Moreover, the intraperitoneal insulin tolerance test and the intraperitoneal glucose tolerance test were employed to evaluate the efficacy of XZF in insulin homeostasis. Hepatocyte oxidative damage markers were detected to assess the efficacy of XZF in preventing oxidative stress. Label-free proteomics was used to investigate the underlying mechanism of XZF in NAFLD. RT-qPCR was used to calculate the expression levels of lipid metabolism genes. Western blot analysis was applied to detect the hepatic protein expression of AMPK, p-AMPK, PPARɑ, CPT1, and PPARγ. RESULTS: 120 compounds were preliminarily identified from XZF by UHPLC-Q-Orbitrap HRMS. XZF could alleviate HFD-induced obesity, white adipocyte size, lipid accumulation, and hepatic steatosis in mice. Additionally, XZF could normalize glucose levels, improve glucolipid metabolism disorders, and prevent oxidative stress damage induced by HFD. Furthermore, the proteomic analysis showed that the major pathways in fatty acid metabolism and the PPAR signaling pathway were significantly impacted by XZF treatment. The expression levels of several lipolytic and β-oxidation genes were up-regulated, while the expression of fatty acid synthesis genes declined in the HFD + XZF group. Mechanically, XZF treatment enhanced the expression of p-AMPK, PPARɑ, and CPT-1 and suppressed the expression of PPARγ in the livers of NAFLD mice, indicating that XZF could activate the AMPK and PPAR pathways to attenuate NALFD progression. CONCLUSION: XZF could attenuate NAFLD by moderating lipid metabolism by activating AMPK and PPAR signaling pathways.
引用
- You L, Wang T, Li W, et al. Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways. J Ethnopharmacol. 2024. PMID: 38588984. doi:10.1016/j.jep.2024.118165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。